Search Here

In an effort to bring some relief to those who have up until now suffered in nauseated silence, NASA's Johnson's Space Center in Houston has signed a contract titled the Space Act Agreement with  Epiomed Therapeutics Inc. of Irvine, Calif to develop and endorse a fast-acting nasal spray to fight motion illness.

The drug, now being called  intranasal scopolamine, or INSCOP, will not only serve to help the many astronauts who often suffer from space sickness, despite whether or not they were previously susceptible to motion sickness,  but the spray will also aid those who are chronically, car and sea sick.

Lakshmi Putcha, developer of the innovative treatment strategy at Johnson said in a statement published by NASA,

"NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas,"

Promising test trials published two years ago in the April 2012 journal Space and Environmental Medicine involved a gel form of INSCOP and suggest that the spray will not only be fast-acting but long-lasting as welll.

NASA and Epiomed will collaborate on clinical trials related to the Federal Drug Administration requirements to test the nasal spray, as army and Naval officials are already clamoring to use the product.

Keep a look out for the medicine in drug stores near you.